Akira Matsuno is the founder of Tune Therapeutics. Tune Therapeutics has raised $200M in total funding. Latest round: Series B. Backed by NEA.
Akira Matsuno is a biotech executive and co-founder of Tune Therapeutics, an epigenome editing company. He serves as Co-Founder, President, COO, and CFO, overseeing financial and operational strategy. Matsuno has been instrumental in raising over $200 million in total funding for the company.
Full founder directory · Investor directory · Company funding database · Fundraising library